期刊文献+

酚红分光光度法测定替米沙坦的含量 被引量:2

Spectrophotometric Determination of Telmisartan with the Reagent Phenol Red
在线阅读 下载PDF
导出
摘要 在pH为7.9的B-R缓冲体系中,酚红与替米沙坦作用,形成离子缔合物,溶液颜色发生改变,其最大显色和褪色波长分别为558,426 nm,替米沙坦的浓度与溶液的增色或褪色呈线性关系,建立了分光光度法测定替米沙坦的含量。在最大显色和褪色波长处,替米沙坦的浓度分别在6.50×10^(-7)~1.35×10^(-5)mol·L^(-1)和7.50×10^(-7)~1.00×10^(-5)mol·L^(-1)范围内遵守比耳定律,摩尔吸光率分别为6.59×10~4,2.12×10~4L·mol^(-1)·cm^(-1),检出限(3δ)分别为1.72×10^(-7),8.53×10^(-7)mol·L^(-1)。用于血样、尿样和药品中替米沙坦的测定,相对标准偏差(n=11)在0.72%~2.56%之间。 In the B-R buffer solution of pH 7.9,an ion-association complex was formed by the reaction of telmisartan with phenol red,having its positive maximum absorption wavelength at 558 nm and the negative maximum absorption wavelength at 426 nm.Ranges of linearity and values of apparent molar absorptivity were found in the positive absorption region and in the negative absorption region were 6.50×10^-7 -1.35×10^-5 mol·L^-1,7.50×10^-7 -1.00×10^-5mol·L^-1,and 6.59×10^4L·mol^-1·cm^-1,2.12×10^4L·mol^-1·cm^-1 respectively.The detection limits(3δ) of the method found were 1.72×10^-7 mol·L^-1 and 8.53×10^-7 mol·L^-1 respectively.The proposed method was applied to the determination of telmisartan in the samples of medicine, human serum and human urine,giving values of RSD(n=11) in the range of 0.72%-2.56%.
出处 《理化检验(化学分册)》 CAS CSCD 北大核心 2010年第4期390-392,395,共4页 Physical Testing and Chemical Analysis(Part B:Chemical Analysis)
基金 重庆市教委科研(KJ081301) 重庆市涪陵区科委科技计划(2008-43) 重庆市高等学校优秀中青年骨干教师资助计划[渝教人(2005)2号] 长江师范学院科研(07Jkg50)资助
关键词 酚红 替米沙坦 分光光度法 Phenol red Telmisartan Spectrophotometry
  • 相关文献

参考文献9

二级参考文献22

  • 1杨梅,邹原,于世钧,李晓辉.阿昔洛韦-过氧化氢-钴(Ⅱ)化学发光体系的研究和应用[J].分析化学,2004,32(9):1237-1239. 被引量:17
  • 2Sharpe M,Jarvis B,Goa KL. Telmisartan:a review of its use in hypertension. Drugs ,2001,61 (10): 1501.
  • 3Torrealday N,Gonza]ez L,Alonso RM, et al. Experimental design approach for the optimization of a HPLC - fluorimetric method for the quantitation of the angiotensin Ⅱ receptor antagonist telmisartan in urine. J Pharm Biomed Anal ,2003,32:847.
  • 4Stangier J, Su CAPF, Brickl R, et al. Pharmacokinetics of single -dose telmisartan 120 mg given during ang between hemodiaysis in subjects with severe renal insufficiency:comparison with healthy volunteers. J Clin Pharmacol ,2000,40(12):1365.
  • 5Stangier J,Schmid J,Turck D, et al. Absorption,metabolism,and excretion of intravenously and orally administered [ 14C ] telmisartan inhealthy volunteers. J Clin Pharmacol ,2000,40(12):1312.
  • 6Stangier J,Su CAPF, Fraunhofer A, et al. Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. J Clin Pharmacol ,2000,40(12):1338.
  • 7Stungier J, Su CAPF, Schondorfer G, et al. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment comparison with healthy volunteers. J Clin Pharmacol ,2000,40(12): 1355.
  • 8McCleLlan KJ, Markham A. Telmisartan. Drugs, 1998,56 (6) : 1039.
  • 9Wienen W,Hauel N,Van Meel JCA,et al. Pharmacological characterization of the novel nonpeptide angitension Ⅱ receptor antagonist,BIBR 277[J].Br J Pharmacol,1993,110(1):245-252.
  • 10Stangier J,Schmid J,Turck D,et al.Absorption,metabolism and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers[J].J Clin Pharmacol,2000,40(12):1312-1322.

共引文献63

同被引文献16

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部